Skip to main content

Day: October 27, 2023

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

SHANGHAI, China, Oct. 27, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the presentation of new clinical trial results at the European Society of Oncologists (“ESMO”) Immuno-Oncology Congress 2023, an international conference held in Madrid, Spain, from October 20th to 24th. At the ESMO Congress 2023, Junshi Bioscience showcased a total of 11 clinical trials involving the groundbreaking immune-oncology drug, toripalimab (anti-PD-1 monoclonal antibody), in the forms of 1 late-breaking abstract, 2 proffered paper oral presentations, and 8 posters. These trials encompass ten diverse fields, including lung cancer, kidney cancer,...

Continue reading

Webcast Alert: Cavco Industries, Inc. Announces Fiscal 2024 Second Quarter Earnings Release and Conference Call Webcast

PHOENIX, Oct. 27, 2023 (GLOBE NEWSWIRE) — Cavco Industries, Inc. (Nasdaq: CVCO) will release earnings for the second quarter ended September 30, 2023 on Thursday, November 2, 2023 after the close of market. Senior management will discuss the results in a live webcast the following day, Friday, November 3, 2023 at 1:00 p.m. Eastern Time. Date:   November 3, 2023 Time:   1:00 p.m. ET            Listen via Internet: https://investor.cavco.com/ Listen via Telephone: To participate in the call, please register here to receive the dial-in number and your unique PIN. If you are unable to participate during the live webcast, the call will be available for 90 days on https://investor.cavco.com/. Cavco Industries, Inc., headquartered in Phoenix, Arizona, designs and produces factory-built housing products primarily distributed through a...

Continue reading

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Positive aggregate safety data from vafidemstat’s fully enrolled PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the drug is safe and well-tolerated Continues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophrenia Continues to recruit patients in FRIDA trial with iadademstat in combination with gilteritinib in relapsed/refractory FLT3-mutant AML patients Research and development (R&D) expenses of $3.8 and $12.2 million for the quarter and nine months ended September 30, 2023, respectivelyMADRID, Spain and BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases...

Continue reading

Hubbell Incorporated Declares 9% Dividend Increase

Shelton, CT, Oct. 27, 2023 (GLOBE NEWSWIRE) — The Board of Directors of Hubbell Incorporated (NYSE:HUBB) today declared a 9% increase in its common stock dividend rate. The new annual payment of $4.88 per share, or $1.22 per quarter, compares to the former rate of $4.48 per share, or $1.12 per quarter. The dividend will be paid on December 15, 2023 to shareholders of record on November 30, 2023. Hubbell Incorporated is a leading manufacturer of utility and electrical solutions enabling customers to operate critical infrastructure reliably and efficiently. With 2022 revenues of $4.9 billion, Hubbell solutions electrify economies and energize communities. The corporate headquarters is located in Shelton, CT. Contact:     Dan Innamorato                   Hubbell Incorporated                   40 Waterview Drive                   P.O...

Continue reading

Innofactor Plc: Share Repurchase 27.10.2023

Innofactor Plc Announcement 27.10.2023          Innofactor Plc: Share Repurchase 27.10.2023       In the Helsinki Stock Exchange         Trade date 27.10.2023  Bourse trade Buy  Share IFA1V  Amount 10,000 SharesAverage price/ share 1.0850 EURTotal cost 10,850.00 EUR          Innofactor Plc now holds a total of 351 889 sharesincluding the shares repurchased on 27.10.2023          On behalf of Innofactor Plc         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       Additional information:    Sami Ensio, CEO    Innofactor Plc    Tel. +358 50 584 2029    sami.ensio@innofactor.com         www.innofactor.com       AttachmentInnofactor_27.10_trades

Continue reading

Oma Savings Bank Plc: Acquisition of own shares 27.10.2023

Oma Savings Bank Plc Stock Exchange Release 27.10.2023          Oma Savings Bank Plc: Acquisition of own shares 27.10.2023     In the NASDAQ OMX Helsinki         Trade date 27.10.2023  Bourse trade Buy  Share OMASP  Amount 4,300 SharesAverage price/ share 20.7055 EURTotal cost 89,033.65 EUR          Company now holds a total of 159 188 shares  including the shares repurchased on 27.10.2023            On behalf of Oma Savings Bank Plc       Nordea Bank Finland Plc         Janne Sarvikivi Sami Huttunen            For further information, please contact:  Sarianna Liiri    CFO    Tel. +358 40 835 6712    sarianna.liiri@omasp.fi         Minna Sillanpää    CCO    Tel. +358 50 66592    minna.sillanpaa@omasp.fi         www.omasp.fi...

Continue reading

Meridian Corporation Reports Third Quarter 2023 Results and Announces a Quarterly Dividend of $0.125 per Common Share

MALVERN, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) — Meridian Corporation (Nasdaq: MRBK) today reported:Net income of $4.0 million and diluted earnings of $0.35 per share for the third quarter ended September 30, 2023. Return on average assets and return on average equity for the third quarter of 2023 were 0.73% and 10.17%, respectively. Net interest margin was 3.29% for the third quarter of 2023, with a loan yield of 7.08%. Total assets at September 30, 2023 and June 30, 2023 were $2.2 billion, compared to $1.9 billion at September 30, 2022. Third quarter overall commercial loan growth was $21.3 million, or 6.1% annualized; residential and home equity loans increased by $15.1 million on a combined basis, or 19.2% annualized. Third quarter deposit growth was $26.0 million, or 6.0% annualized. Raised $9.7 million in subordinated debt...

Continue reading

Axalta Named Exclusive Supplier for BMW Group’s Private Paint Label ColorSystem in EMEA

Adds to existing supplier agreements Up to 45% reduction in carbon equivalent emissions across 730 franchised dealer collision repair shops GLEN MILLS, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) — Axalta Coating Systems (NYSE: AXTA), a leading global coatings company, has been named exclusive supplier for BMW Group’s private paint label, ColorSystem, in currently 15 Europeans countries plus South Africa. The agreement includes BMW Group’s network of 730 dealerships and collision repair partners. BMW Group’s ColorSystem is engineered to be one of the world’s most technologically advanced paint systems. It offers refinishing solutions that meet BMW Group’s original manufacturer standards. “The BMW Group selects only the best products for its dealerships and collision repair partners to ensure the highest standards of quality, efficiency...

Continue reading

Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

Psychemedics’ FDA-cleared alternative 5-panel drug screen replaces marijuana with fentanyl. ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) — In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl. Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is a leap forward in drug screening technology. As we grapple with an ongoing labor shortage and with marijuana’s legal landscape evolving in 49 states, it’s clear that the time for a change has come. Traditional 5-panel drug tests,...

Continue reading

Sunrise New Energy Announces Successful Development of New Generation Porous Carbon-coated Silicon Anode Material with 5 Times the Capacity of Existing Artificial Graphite, Enabling 1,000 Kilometer Range for Electric Vehicle Batteries

ZIBO, China, Oct. 27, 2023 (GLOBE NEWSWIRE) —  Sunrise New Energy Co., Ltd. (“Sunrise”, the “Company”, “we” or “our”) (NASDAQ: EPOW), today announced the successful development of the latest generation of porous carbon-coated silicon anode material, offering a capacity five times higher than existing artificial graphite. This breakthrough material can be applied to electric vehicle batteries, enabling a range of 1,000 kilometers. The technical team at Sunrise (Guizhou) New Energy Materials Co., Ltd. has dedicated nearly two years of intensive efforts to achieve this significant milestone. The new porous carbon-coated silicon anode material surpasses traditional artificial graphite in terms of capacity, providing a remarkable advancement in electric vehicle battery technology. Additionally, it effectively reduces the high expansion...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.